Advanced search
Publication Cover
Minimally Invasive Therapy & Allied Technologies Volume 26, 2017 - Issue 4
Submit an article Journal homepage
201
Views
4
CrossRef citations to date
0
Altmetric
Original Article

Safety and efficacy of HepaSphere 50–100 μm in the treatment of hepatocellular carcinoma

Charles Edouard ZurstrassenInterventional Radiology Department, A.C. Camargo Cancer Center, São Paulo, Brazil; Correspondence[email protected]
,
Luiz Paulo De Oliveira GireliInterventional Radiology Department, A.C. Camargo Cancer Center, São Paulo, Brazil;
,
Chiang Jeng TyngInterventional Radiology Department, A.C. Camargo Cancer Center, São Paulo, Brazil;
,
Almir Galvão Vieira BitencourtImaging Department, A.C. Camargo Cancer Center, São Paulo, Brazil;
,
Marcos Duarte GuimarãesImaging Department, A.C. Camargo Cancer Center, São Paulo, Brazil;
,
Paula Nicole Vieira BarbosaImaging Department, A.C. Camargo Cancer Center, São Paulo, Brazil;
,
Aline Cristine Barbosa Santos CavalcanteInterventional Radiology Department, A.C. Camargo Cancer Center, São Paulo, Brazil;
,
João Paulo Matushita JuniorInterventional Radiology Department, A.C. Camargo Cancer Center, São Paulo, Brazil;
,
Mauricio Kauark AmoedoInterventional Radiology Department, A.C. Camargo Cancer Center, São Paulo, Brazil;
,
Felipe Jose CoimbraAbdominal Surgery Department, A.C. Camargo Cancer Center, São Paulo, Brazil;
,
Rogério Camargo Pinheiro AlvesHepatology Department, A.C. Camargo Cancer Center, São Paulo, Brazil
&
Rubens ChojniakImaging Department, A.C. Camargo Cancer Center, São Paulo, Brazil;
show all
Pages 212-219 | Received 25 Jan 2016, Accepted 16 Jan 2017, Published online: 14 Feb 2017

References

  • Langer LF, Gonzalez AM, Amorim JE, Ajzen AS. Contribution of transcatheter arterial chemoembolization of hepatocellular carcinomas in cirrhotic patients awaiting liver transplantation. Radiol Bras 2005;38:1–6.
  • Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153–6.
  • Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010;33:41–52.
  • Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 1999;19:329–38.
  • Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002;35:519–24.
  • Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164–71.
  • Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734–9.
  • Malagari K, Pomoni M, Moschouris H, Kelekis A, Charokopakis A, Bouma E, et al. Chemoembolization of hepatocellular carcinoma with HepaSphere 30-60 μm. Safety and efficacy study. Cardiovasc Intervent Radiol 2014;37:165–75.
  • Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol 2012;56:1330–5.
  • Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020–2.
  • Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208–36.
  • Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;6:646–9.
  • Sorensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. An inter-observer variability study. Br J Cancer 1993;67:773–5.
  • Lencioni R, Llover JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52–60.
  • Food and Drug Administration (FDA). Guidance for Industry - Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. 2007. Available at: http://www.fda.gov/downloads/Drugs/…/Guidances/ucm071590.pdf. [Accessed September 09, 2016].
  • Agresti A. An Introduction to Categorical Data Analysis. New York: John Wiley & Sons. 2007.
  • Hollander M, Wolfe DA. Nonparametric Statistical Methods. New York: John Wiley & Sons. 1973.
  • Fleming TH, Harrington DP. Nonparametric estimation of the survival distribution in censored data. Commun Stat 1984;13:2469–86.
  • R Core Team. R software environment for statistical computing and graphics version 3.1.1. R Foundation for Statistical Computing. 2014. Available at: https://cran.r-project.org/src/base/R-3/. [Accessed December 01, 2015].
  • Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer 2014;111:255–64.
  • Arabi M, BenMousa A, Bzeizi K, Garad F, Ahmed I, Al-Otaibi M. Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma. Saudi J Gastroenterol 2015;21:175–80.
  • Song MJ, Chun HJ, Song DS, Kim HY, Yoo SH, Park CH, et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 2012;57:1244–50.
  • Grosso M, Vignali C, Quaretti P, Nicolini A, Melchiorre F, Gallarato G, et al. Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicentre study. Cardiovasc Intervent Radiol 2008;31:1141–9.
  • Seki A, Hori S, Kobayashi K. Transcatheter Arterial Chemoembolization with Epirrubicin-Loaded Superabsorbent Polymer Microspheres for 135 Hepatocellular Carcinoma Patients: Single-Center Experience. Cardiovasc Intervent Radiol 2011;34:557–65.
  • Button KS, Ioannidis JP, Mokrysz C, Nosek BA, Flint J, Robinson ES, et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci 2013;14:365–76.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.